Elamipretide vs Macimorelin
Head-to-head comparison of Elamipretide (Elamipretide (MTP-131, SS-31)) and Macimorelin (Macimorelin acetate (AEZS-130)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Elamipretide | Macimorelin |
|---|---|---|
| Category | Muscle & Performance | Growth Hormone |
| Full Name | Elamipretide (MTP-131, SS-31) | Macimorelin acetate (AEZS-130) |
| Molecular Weight | 639.8 Da | N/A |
| Half-Life | 1-4 hours | about 4-6 hours |
| Amino Acids | 4 | N/A |
| Typical Dose | 0.01-0.25 mg/kg/day | 0.5 mg/kg single oral dose |
| Route | Subcutaneous/Intravenous | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 120 |
| Research Status | Clinical | Clinical |
Elamipretide Benefits
- ✓mitochondrial protection
- ✓reduced oxidative stress
- ✓improved fatigue resistance
- ✓may support exercise tolerance
Macimorelin Benefits
- ✓diagnostic GH stimulation
- ✓single oral dose
- ✓rapid measurable GH response
- ✓high clinical utility
Elamipretide Dosing
0.01-0.25 mg/kg/day SC (clinical research)|daily dosing in trials|alternative IV protocols in some studies
Macimorelin Dosing
0.5 mg/kg orally as a single dose|fasted testing conditions|serial GH sampling after administration
Elamipretide Side Effects
- ⚠nausea
- ⚠injection-site reactions
- ⚠diarrhea
- ⚠headache
Macimorelin Side Effects
- ⚠dysgeusia or taste disturbance
- ⚠nausea
- ⚠headache
Research Overview
Elamipretide
Clinical and translational studies show elamipretide can improve mitochondrial function and some functional endpoints in mitochondrial disorders. Skeletal muscle research suggests benefits are driven by energy metabolism rather than direct muscle-building effects.
Macimorelin
Macimorelin has been validated in clinical testing as an oral alternative to injectable GH stimulation tests. Its short-term use makes it a useful translational tool for evaluating pituitary GH reserve.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.